$UNCY
Unicycive Therapeutics, Inc. Stock $uncy

$uncy Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000121390023040161 Filed on May 16, 2023

Income Statement

Concept	2023 Q2	2023 Q1	2022 Q4
Revenue		$675.0K	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$193.0K	$62.00K	$1.485M
YoY Change	0.0%	-96.13%	6.76%
% of Gross Profit
Research & Development	$2.267M	$3.030M	$3.840M
YoY Change	21.88%	56.75%	182.15%
% of Gross Profit
Depreciation & Amortization	$2.000K	$2.000K	$2.000K
YoY Change	0.0%	0.0%	100.0%
% of Gross Profit
Operating Expenses	$4.322M	$4.877M	$5.325M
YoY Change	18.87%	37.89%	93.5%
Operating Profit	-$4.322M	-$4.202M
YoY Change	18.87%
Interest Expense	$32.00K	$12.00K	-$3.000K
YoY Change
% of Operating Profit
Other Income/Expense, Net	$282.0K	-$10.38M	$0.00
YoY Change
Pretax Income	-$3.838M	-$14.58M	-$5.328M
YoY Change	5.56%	312.07%	93.6%
Income Tax
% Of Pretax Income
Net Earnings	-$3.838M	-$14.58M	-$5.328M
YoY Change	5.56%	312.07%	93.6%
Net Earnings / Revenue		-2159.26%
Basic Earnings Per Share	-$0.29	-$0.97
Diluted Earnings Per Share	-$0.29	-$0.97	-$0.35
COMMON SHARES
Basic Shares Outstanding	15.23M shares	15.23M shares	15.09M shares
Diluted Shares Outstanding	15.23M shares	15.23M shares

Balance Sheet

Concept	2023 Q2	2023 Q1	2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$18.82M	$24.33M	$455.0K
YoY Change	77.98%	78.65%	-97.26%
Cash & Equivalents	$18.82M	$24.33M	$455.0K
Short-Term Investments
Other Short-Term Assets	$3.112M	$1.852M	$2.189M
YoY Change	56.62%	0.43%	19.49%
Inventory	$3.112M	$1.852M	$2.189M
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$21.93M	$26.18M	$2.644M
YoY Change	74.6%	69.32%	-85.64%
LONG-TERM ASSETS
Property, Plant & Equipment	$30.00K	$21.00K	$22.00K
YoY Change	15.38%	-92.91%	-21.43%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$953.0K	$1.018M	$174.0K
YoY Change	272.27%	243.92%	-47.75%
TOTAL ASSETS
Total Short-Term Assets	$21.93M	$26.18M	$2.644M
Total Long-Term Assets	$953.0K	$1.018M	$174.0K
Total Assets	$22.88M	$27.20M	$2.818M
YoY Change	78.55%	72.6%	-84.97%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$503.0K	$790.0K	$892.0K
YoY Change	-32.66%	34.13%	20.22%
Accrued Expenses	$1.689M	$1.698M	$2.237M
YoY Change	-12.35%	-6.34%	84.57%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$15.42M	$15.97M	$3.284M
YoY Change	444.07%	564.86%	56.01%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$634.0K	$715.0K	$0.00
YoY Change	780.56%	527.19%	-100.0%
Total Long-Term Liabilities	$634.0K	$715.0K	$0.00
YoY Change	780.56%	527.19%	-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$15.42M	$15.97M	$3.284M
Total Long-Term Liabilities	$634.0K	$715.0K	$0.00
Total Liabilities	$16.05M	$16.69M	$3.284M
YoY Change	452.41%	563.16%	45.31%
SHAREHOLDERS EQUITY
Retained Earnings	-$52.41M	-$48.57M	-$34.00M
YoY Change	126.77%		113.29%
Common Stock	$15.00K	$15.00K	$15.00K
YoY Change	0.0%		0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$19.37M	-$15.08M	-$466.0K
YoY Change
Total Liabilities & Shareholders Equity	$22.88M	$27.20M	$2.818M
YoY Change	78.55%	72.6%	-84.97%

Cashflow Statement

Concept	2023 Q2	2023 Q1	2022 Q4
OPERATING ACTIVITIES
Net Income	-$3.838M	-$14.58M	-$5.328M
YoY Change	5.56%	312.07%	93.6%
Depreciation, Depletion And Amortization	$2.000K	$2.000K	$2.000K
YoY Change	0.0%	0.0%	100.0%
Cash From Operating Activities	-$5.502M	-$3.920M	-$6.084M
YoY Change	80.57%	32.57%	333.64%
INVESTING ACTIVITIES
Capital Expenditures	$12.00K		$0.00
YoY Change			-100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$12.00K		$0.00
YoY Change			-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid		$200.0K
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	$27.80M	-471.0K
YoY Change
NET CHANGE
Cash From Operating Activities	-5.502M	-$3.920M	-6.084M
Cash From Investing Activities	-12.00K		0.000
Cash From Financing Activities	0.000	$27.80M	-471.0K
Net Change In Cash	-5.514M	$23.88M	-6.555M
YoY Change	80.96%		357.75%
FREE CASH FLOW
Cash From Operating Activities	-$5.502M	-$3.920M	-$6.084M
Capital Expenditures	$12.00K		$0.00
Free Cash Flow	-$5.514M	-$3.920M	-$6.084M
YoY Change	80.96%	32.66%	342.79%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.97
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	001-40582
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	81-3638692
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	4300 El Camino Real
CY2023Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 210
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Los Altos
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94022
CY2023Q1	dei	City Area Code CityAreaCode	(650)
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	351-4495
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023Q1	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q1	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
CY2023Q1	dei	Trading Symbol TradingSymbol	UNCY
CY2023Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	15233836	shares
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	455000	usd
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	24332000	usd
CY2022Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	2189000	usd
CY2023Q1	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	1852000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	2644000	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	26184000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	152000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	997000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	22000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	21000	usd
CY2022Q4	us-gaap	Assets Assets	2818000	usd
CY2023Q1	us-gaap	Assets Assets	27202000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	892000	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	790000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2237000	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1698000	usd
CY2023Q1	us-gaap	Derivative Liabilities DerivativeLiabilities	13206000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	155000	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	276000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3284000	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	15970000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	715000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	3284000	usd
CY2023Q1	us-gaap	Liabilities Liabilities	16685000	usd
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	30190	shares
CY2023Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	30190	shares
CY2023Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	30190	shares
CY2023Q1	us-gaap	Preferred Stock Liquidation Preference Value PreferredStockLiquidationPreferenceValue	30600	usd
CY2023Q1	us-gaap	Temporary Equity Value Excluding Additional Paid In Capital TemporaryEquityValueExcludingAdditionalPaidInCapital	25599000	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	15231655	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	15231655	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	15233836	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	15233836	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	15000	usd
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	15000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	33516000	usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	33475000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-33997000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-48572000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-466000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-15082000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2818000	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	27202000	usd
CY2023Q1	us-gaap	Revenues Revenues	675000	usd
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1933000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3030000	usd
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1604000	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1847000	usd
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	3537000	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	4877000	usd
CY2022Q1	uncy	Loss On Debt Conversion LossOnDebtConversion	-3537000	usd
CY2023Q1	uncy	Loss On Debt Conversion LossOnDebtConversion	-4202000	usd
CY2023Q1	us-gaap	Interest Income Other InterestIncomeOther	14000	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	12000	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-10375000	usd
CY2023Q1	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-10373000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-3537000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-14575000	usd
CY2023Q1	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	192000	usd
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3537000	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-14767000	usd
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.24
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.97
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	15004617	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	15232406	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	16484000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-3537000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	7000	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	290000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	13244000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-466000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-14575000	usd
CY2023Q1	us-gaap	Dividends Preferred Stock DividendsPreferredStock	192000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	7000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	144000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-15082000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-3537000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-14575000	usd
CY2022Q1	us-gaap	Depreciation Depreciation	2000	usd
CY2023Q1	us-gaap	Depreciation Depreciation	2000	usd
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	290000	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	144000	usd
CY2023Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	10375000	usd
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	37000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	43000	usd
CY2022Q1	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-263000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-338000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	24000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-193000	usd
CY2022Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-36000	usd
CY2023Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-54000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2957000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3920000	usd
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2000	usd
CY2023Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	240000	usd
CY2023Q1	uncy	Issuance Of Common Stock For Cash Net Of Issuance Costs IssuanceOfCommonStockForCashNetOfIssuanceCosts	2153000	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	30190000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	27797000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-2959000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	23877000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	16579000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	455000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	13620000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	24332000	usd
CY2023Q1	us-gaap	Stock Issued1 StockIssued1	192000	usd
CY2023Q1	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	2831000	usd
CY2022Q1	uncy	Deferred Insurance Charges Included In Prepaid Expenses And Other Current Assets DeferredInsuranceChargesIncludedInPrepaidExpensesAndOtherCurrentAssets	275000	usd
CY2023Q1	uncy	Deferred Insurance Charges Included In Prepaid Expenses And Other Current Assets DeferredInsuranceChargesIncludedInPrepaidExpensesAndOtherCurrentAssets	121000	usd
CY2023Q1	uncy	Licensing Revenue LicensingRevenue	700000	usd
CY2022Q4	uncy	Accmulated Deficit AccmulatedDeficit	34000000	usd
CY2023Q1	uncy	Accmulated Deficit AccmulatedDeficit	48600000	usd
CY2023Q1	uncy	Purchase Agreement PurchaseAgreement	130000000	usd
CY2023Q1	uncy	Gross Proceeds GrossProceeds	30000000	usd
CY2023Q1	uncy	Financial Term FinancialTerm	P1Y
CY2023Q1	uncy	Income Tax Largest Amount IncomeTaxLargestAmount	0.50	pure
CY2023Q1	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Use of Estimates</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the periods presented. Management believes that these estimates and assumptions are reasonable; however, actual results may differ and could have a material effect on future results of operations and financial position. Significant items subject to such estimates and assumptions include revenues, stock-based compensation, research contract accruals and prepaid amounts, and the fair value of warrant liabilities. Actual results may materially differ from those estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p>
CY2022Q3	uncy	Royalties Percentage RoyaltiesPercentage	0.07	pure
CY2022Q3	uncy	Regulatory And Commercial Achievements Percentage RegulatoryAndCommercialAchievementsPercentage	0.10	pure
CY2023Q1	us-gaap	Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Other Percentage Of Nonperforming Assets AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureOtherPercentageOfNonperformingAssets	0.21	pure
CY2023Q1	us-gaap	Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Other Percentage Of Nonperforming Assets AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureOtherPercentageOfNonperformingAssets	0.05	pure
CY2023Q1	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	13206000	usd
CY2023Q1	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	13206000	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	2831000	usd
CY2023Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	10375000	usd
CY2023Q1	us-gaap	Fair Value Net Asset Liability FairValueNetAssetLiability	13206000	usd
CY2022Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	10375000	usd
CY2023Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Concentration of Credit Risk</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial instruments that potentially subject the Company to concentration of credit risk consist of cash and cash equivalents. All of the Company’s cash was deposited in one account at a financial institution during 2022, and cash balances may at times exceed federally insured limits. For 2023 the Company’s cash is distributed across multiple financial institutions. The cash and cash equivalents the Company uses to satisfy working capital and operating expense needs are currently held in accounts at various financial institutions. Cash and cash equivalents could be adversely impacted, including the loss of uninsured deposits and other uninsured financial assets, if one or more of the financial institutions in which the Company holds its cash or cash equivalents fails or is subject to other adverse conditions in the financial or credit markets.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p>
CY2022Q4	us-gaap	Fair Value Net Asset Liability FairValueNetAssetLiability		usd
CY2023Q1	uncy	Significant Agreements Policies SignificantAgreementsPolicies	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>3. Significant Agreements</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">With regards to manufacturing, testing and potential commercial supply of Renazorb, the Company has entered into an agreement with Shilpa Medicare Ltd based in India. According to the terms of the agreement Unicycive will pay the vendor $2 million in the first calendar year when the net revenue reaches $10 million from sales of Renazorb following its approval by the FDA and commercial supply of the product by the vendor (First Payment). Thereafter, the Company will pay $2 million per year for four consecutive years, after the first year’s payment, for the total payments of $10 million, provided all commercial supplies are continued to be manufactured and supplied by the vendor. Unicycive is not obligated to make any payments to the vendor until FDA approval of the product is obtained and commercial revenue is generated.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In October 2017, the Company entered into an exclusive license agreement with Sphaera, a stockholder, for the rights to further develop the drug candidate, UNI 494, for commercialization. No payments were made upon execution of the agreement but rather payments for $50,000 will be due commencing with the initiation by the Company of a second clinical trial and $50,000 on completion of such trial. At the time the FDA accepts a NDA application submitted by the Company for the product, the Company will pay Sphaera $1.65 million. Upon commercialization and sale of the drug product, royalty payments will also be payable quarterly to Sphaera equal to 2% of net sales on the preceding quarter.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In September 2018, the Company entered into an Assignment and Asset Purchase Agreement with Spectrum Pharmaceuticals, Inc. (“Spectrum Agreement”) pursuant to which the Company purchased certain assets from Spectrum, including Spectrum’s right, title, interest in and intellectual property related to Renazorb RZB 012, also known as RENALAN™ (“Renalan”) and RZB 014, also known as SPI 014 (“SPI” and together with Renalan, the “Compounds”), to further develop and commercialize Renazorb and related compounds. In partial consideration for the Spectrum Agreement, the Company issued 313,663 shares of common stock to Spectrum valued at approximately $4,000 which represented four percent of the Company on a fully-diluted basis at the date of the execution of the Spectrum Agreement. The Spectrum Agreement has an anti-dilution provision, which provides that Spectrum maintain its ownership interest in the Company at 4% of the Company’s shares on a fully-diluted basis. Fully-diluted shares of common stock for purposes of the Renazorb Purchase Agreement assumes conversion of any security convertible into or exchangeable or exercisable for common stock or any combination thereof, including any common stock reserved for issuance under a stock option plan, restricted stock plan, or other equity incentive plan approved by the Board of Directors of the Company immediately following the issuance of additional shares of the Company’s common stock (but prior to the issuance of any additional shares of common stock to Spectrum). Spectrum’s ownership shall not be subject to dilution until the earlier of thirty-six months from the first date the Company’s stock trades on a public market, or the date upon which the Company attains a public market capitalization of at least $50 million. On July 13, 2021, the Company’s initial public offering resulted in a public market capitalization of at least $50 million, and as a result the Company was required to issue 438,374 anti-dilution shares of common stock. This issuance represented the final anti-dilution calculation required under the Spectrum Agreement, and no further anti-dilution shares will be issued. The Company calculated the fair value of the shares and recognized $2.2 million to research and development expenses as cost to issue those shares during the third quarter of 2021. In the event an NDA filing for Renazorb is accepted by the FDA, the Company will be required to pay $0.2 million to Altair Nanomaterials, Inc., (“Altair”) in accordance with the Spectrum Agreement. In addition, in the event FDA approval for Renazorb is received, the Company will be required to pay $4.5 million to Altair. The Company is also required to pay Spectrum 40% of all of the Company’s sublicense income for any sublicense granted to certain sublicensees during the first 12 months after the Closing Date (as that term is defined in the Renazorb Purchase Agreement) and 20% of all other sublicense income. The Company’s payment obligations to Spectrum will expire on the twentieth (20<sup>th</sup>) anniversary of the Closing Date of the Renazorb Purchase Agreement. In August 2022, the Company received an upfront payment of approximately $1.0 million as a result of a sublicense development agreement with Lee’s Pharmaceutical (HK) Limited. The payment represents sublicense income as described in the Spectrum Agreement, and 20% of the amount received has been accrued as an R&D expense in the accompanying statements of operations for the year ended December 31, 2022. In February 2023, the Company received an upfront payment of approximately $0.7 million as a result of a sublicense development agreement with Lotus International Pte Ltd. The payment represents sublicense income as described in the Spectrum Agreement, and 20% of the amount received has been accrued as an R&D expense in the accompanying statements of operations for the three months ended March 31, 2023.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 19, 2021, the Company entered into an agreement with Syneos Health LLC (“Syneos”) pursuant to which Syneos will provide preclinical research and analysis services related to the development of UNI-494. The initial budget for the study, which includes clinical pharmacology, translational sciences, and bioanalytical services, was approximately $2.3 million. Related payments totaling approximately $2.0 million have been paid to Syneos as of March 31, 2023.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 6, 2022, the Company entered into a Master Services Agreement with Quotient Sciences Limited (“Quotient”), a UK based company that provides drug development and analysis services, for the purpose of performing clinical research in support of UNI-494. The initial budget for the study is approximately $3.7 million, and subsequent revisions reduced the overall budget to $2.6 million. Related payments totaling approximately $1.9 million have been paid to Quotient as of March 31, 2023, approximately $0.9 million of related expense has been recorded, and approximately $1.0 million has been recorded as prepaid expense in the accompanying balance sheet as of March 31, 2023.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 9, 2022, the Company entered into a Master Services Agreement with CBCC Global Research Inc. (“CBCC”), a California based company that provides clinical trial and related services, for the purpose of performing clinical research in support of Renazorb. The budget for the initial study was approximately $1.4 million. Payments relating to the initial agreement totaling approximately $0.4 million have been paid to CBCC as of March 31, 2023, and approximately $0.4 million of related expense has been recorded. In September 2022, a statement of work revised the remaining services budget to approximately $0.1 million.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 29, 2022, the Company entered into an Agreement with Inotiv, an Indiana based company that provides preclinical trial and related services, for the purpose of performing research in support of Renazorb. The budget for the services is approximately $1.0 million. Approximately $0.8 million has been paid to Inotiv as of March 31, 2023 and approximately $0.1 million has been recorded as prepaid expense in the accompanying balance sheet as of March 31, 2023.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 14, 2022, the Company entered into a license agreement with Lee’s Pharmaceutical (HK) Limited (see Note 4). Under the terms of the agreement, Lee’s Pharmaceutical will be responsible for development, registration filing and approval for Renazorb in China, Hong Kong, and certain other Asian markets. In addition, Lee’s Pharmaceutical will have sole responsibility for the importation of the drug product from the Company and for the costs of commercialization of Renazorb in the licensed territories. The Company has received an upfront payment of $1.0 million, expects to receive up to $1.0 million in milestone payments upon product launch in China and will be eligible for tiered royalties of between 7% and 10% upon achievement of prespecified regulatory and commercial achievements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 27, 2022, the Company entered into an Agreement with Celerion, a Nebraska based company that provides clinical trial and related services, for the purpose of performing research in support of Renazorb. The budget for the services is approximately $2.7 million, and approximately $2.7 million has been paid to Celerion as of March 31, 2023.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 1, 2023, the Company entered into a license agreement with Lotus International Pte Ltd. (“Lotus”) (see Note 4). Under the terms of the agreement, Lotus will be responsible for development, registration filing and approval for Renazorb in the licensed territory of South Korea. In addition, Lotus will have sole responsibility for the importation of the drug product from the Company and for the costs of commercialization of Renazorb in the licensed territory. The Company has received an upfront payment of $0.7 million, may receive up to $3.7 million in future milestone payments and will be eligible for tiered royalties upon achievement of specified commercial achievements.</p>
CY2023Q1	us-gaap	Debt Instrument Description DebtInstrumentDescription	According to the terms of the agreement Unicycive will pay the vendor $2 million in the first calendar year when the net revenue reaches $10 million from sales of Renazorb following its approval by the FDA and commercial supply of the product by the vendor (First Payment). Thereafter, the Company will pay $2 million per year for four consecutive years, after the first year’s payment, for the total payments of $10 million, provided all commercial supplies are continued to be manufactured and supplied by the vendor.
CY2017Q4	us-gaap	Broadcasters License Agreement Commitments Description BroadcastersLicenseAgreementCommitmentsDescription	No payments were made upon execution of the agreement but rather payments for $50,000 will be due commencing with the initiation by the Company of a second clinical trial and $50,000 on completion of such trial. At the time the FDA accepts a NDA application submitted by the Company for the product, the Company will pay Sphaera $1.65 million. Upon commercialization and sale of the drug product, royalty payments will also be payable quarterly to Sphaera equal to 2% of net sales on the preceding quarter.
CY2021Q3	us-gaap	Capitalization Longterm Debt And Equity CapitalizationLongtermDebtAndEquity	50000000	usd
CY2021Q3	us-gaap	Incremental Common Shares Attributable To Equity Forward Agreements IncrementalCommonSharesAttributableToEquityForwardAgreements	438374	shares
	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	2200000	usd
	uncy	Purchase Agreement Description PurchaseAgreementDescription	The Company is also required to pay Spectrum 40% of all of the Company’s sublicense income for any sublicense granted to certain sublicensees during the first 12 months after the Closing Date (as that term is defined in the Renazorb Purchase Agreement) and 20% of all other sublicense income. The Company’s payment obligations to Spectrum will expire on the twentieth (20th) anniversary of the Closing Date of the Renazorb Purchase Agreement.
CY2022Q3	us-gaap	Debt Instrument Periodic Payment DebtInstrumentPeriodicPayment	1000000	usd
CY2022	uncy	Concentration Risk Percentage ConcentrationRiskPercentage	0.20	pure
CY2023Q1	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	2000000	usd
CY2022Q1	uncy	Revisions Reduced The Overall Budget RevisionsReducedTheOverallBudget	2600000	usd
CY2023Q1	us-gaap	Prepaid Expense Other Noncurrent PrepaidExpenseOtherNoncurrent	1000000	usd
CY2022Q3	us-gaap	Discontinued Operation Amounts Of Material Contingent Liabilities Remaining DiscontinuedOperationAmountsOfMaterialContingentLiabilitiesRemaining	100000	usd
CY2022Q3	us-gaap	Defined Benefit Plan Funded Percentage DefinedBenefitPlanFundedPercentage	0.10	pure
CY2023Q1	uncy	Budget For Services BudgetForServices	2700000	usd
CY2023Q1	us-gaap	Proceeds From Fees Received ProceedsFromFeesReceived	700000	usd
CY2023Q1	us-gaap	Proceeds From Other Deposits ProceedsFromOtherDeposits	3700000	usd
CY2022	us-gaap	Proceeds From License Fees Received ProceedsFromLicenseFeesReceived	1000000	usd
CY2023Q1	us-gaap	Debt And Equity Securities And Foreign Currency Transaction Price Change Unrealized Gain Loss Operating Before Tax DebtAndEquitySecuritiesAndForeignCurrencyTransactionPriceChangeUnrealizedGainLossOperatingBeforeTax	675000	usd
CY2023Q1	uncy	Transaction Price TransactionPrice	675000	usd
CY2023Q1	us-gaap	Proceeds From License Fees Received ProceedsFromLicenseFeesReceived	675000	usd
CY2022Q4	us-gaap	Prepaid Insurance PrepaidInsurance	476000	usd
CY2023Q1	us-gaap	Prepaid Insurance PrepaidInsurance	337000	usd
CY2022Q4	uncy	Prepaid Preclinical Services PrepaidPreclinicalServices	1554000	usd
CY2023Q1	uncy	Prepaid Preclinical Services PrepaidPreclinicalServices	1196000	usd
CY2022Q4	us-gaap	Other Assets Miscellaneous Current OtherAssetsMiscellaneousCurrent	159000	usd
CY2023Q1	us-gaap	Other Assets Miscellaneous Current OtherAssetsMiscellaneousCurrent	319000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	2189000	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	1852000	usd
CY2022Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	15000	usd
CY2023Q1	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	15000	usd
CY2022Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	14000	usd
CY2023Q1	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	14000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	29000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	29000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	7000	usd
CY2023Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	8000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	22000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	21000	usd
CY2022Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	846000	usd
CY2023Q1	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	610000	usd
CY2022Q4	uncy	Credit Card Liability CreditCardLiability	46000	usd
CY2023Q1	uncy	Credit Card Liability CreditCardLiability	180000	usd
CY2022Q4	us-gaap	Accounts Payable Current And Noncurrent AccountsPayableCurrentAndNoncurrent	892000	usd
CY2023Q1	us-gaap	Accounts Payable Current And Noncurrent AccountsPayableCurrentAndNoncurrent	790000	usd
CY2022Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	191000	usd
CY2022Q4	uncy	Accrued Labor Costs AccruedLaborCosts	1487000	usd
CY2023Q1	uncy	Accrued Labor Costs AccruedLaborCosts	610000	usd
CY2022Q4	uncy	Accrued Drug Development Costs AccruedDrugDevelopmentCosts	228000	usd
CY2023Q1	uncy	Accrued Drug Development Costs AccruedDrugDevelopmentCosts	766000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	522000	usd
CY2023Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	322000	usd
CY2022Q4	us-gaap	Accrued Reclamation Costs Current AccruedReclamationCostsCurrent	2237000	usd
CY2023Q1	us-gaap	Accrued Reclamation Costs Current AccruedReclamationCostsCurrent	1698000	usd
CY2023Q1	us-gaap	Lessee Finance Lease Renewal Term1 LesseeFinanceLeaseRenewalTerm1	P3Y
CY2023Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	44000	usd
CY2023Q1	uncy	Operating Lease Right Of Use Assets OperatingLeaseRightOfUseAssets	1000000	usd
CY2023Q1	us-gaap	Lease Cost LeaseCost	65000	usd
CY2023Q1	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	54000	usd
CY2023Q1	uncy	Received Advances From The Stockholder ReceivedAdvancesFromTheStockholder	210000	usd
CY2023Q1	uncy	Repaid Amounts Owed To The Stockholder RepaidAmountsOwedToTheStockholder	210000	usd
CY2017Q3	us-gaap	Stock Issued During Period Shares Other StockIssuedDuringPeriodSharesOther	62181	shares
CY2017Q3	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.013
CY2022	uncy	Professional And Contract Services Expens ProfessionalAndContractServicesExpens	6000	usd
CY2022	us-gaap	Related Party Transaction Terms And Manner Of Settlement RelatedPartyTransactionTermsAndMannerOfSettlement	June 30, 2022
CY2023Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	62000	usd
CY2022Q1	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	290000	usd
CY2023Q1	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	144000	usd
CY2023Q1	uncy	Annual Net Cash Flow From Operations Percentage AnnualNetCashFlowFromOperationsPercentage	0.75	pure
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue		usd
CY2023Q1	uncy	Weighted Average Exercise Price Warrants Granted WeightedAverageExercisePriceWarrantsGranted
CY2022	us-gaap	Multiemployer Plan Employer Contribution Cost MultiemployerPlanEmployerContributionCost	60000	usd
CY2023Q1	us-gaap	Multiemployer Plan Employer Contribution Cost MultiemployerPlanEmployerContributionCost	21000	usd
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q3	us-gaap	Share Price SharePrice	5
CY2021Q3	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P5Y
CY2023Q1	us-gaap	Conversion Of Stock Shares Converted1 ConversionOfStockSharesConverted1	736773	shares
CY2023Q1	us-gaap	Conversion Of Stock Shares Issued1 ConversionOfStockSharesIssued1	184193	shares
CY2023Q1	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P5Y
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	4784193	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P3Y6M14D
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	4784193	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P3Y3M14D
CY2022Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	10000000	shares
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Shares Issued SharesIssued	30190	shares
CY2023Q1	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	28000000	usd
CY2023Q1	us-gaap	Proceeds From Sale Of Trust Assets To Pay Expenses ProceedsFromSaleOfTrustAssetsToPayExpenses	2200000	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment		usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
CY2022Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments		usd
CY2022Q1	uncy	Issuance Of Common Stock For Cash Net Of Issuance Costs IssuanceOfCommonStockForCashNetOfIssuanceCosts		usd
CY2022Q1	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock		usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities		usd
CY2022Q1	us-gaap	Stock Issued1 StockIssued1		usd
CY2023Q1	us-gaap	Conversion Of Stock Description ConversionOfStockDescription	(i) shares of common stock of the Company and, if applicable, shares of Series A-2 Preferred Stock, in lieu of Common Stock, (ii) a tranche A warrant to acquire approximately 46,675,940 shares of Series A-3 Preferred Stock (the “Tranche A Warrant”), (iii) a tranche B warrant to acquire approximately 42,432,672 shares of Series A-4 Preferred Stock (the “Tranche B Warrant”), and (iv) a tranche C warrant to acquire approximately 67,892,276 shares of Series A-5 Preferred Stock (the “Tranche C Warrant”, together with the Tranche A Warrant and the Tranche B Warrant, the “Warrants”). The Tranche A warrants for an aggregate exercise price of approximately $25 million are exercisable until 21 days following the Company’s announcement of receipt of FDA approval for Renazorb, the Tranche B warrants for an aggregate exercise price of approximately $25 million are exercisable until 21 days following the Company’s announcement of receipt of Transitional Drug Add-On Payment Adjustment (“TDAPA”) approval for Renazorb, and the Tranche C Warrant for an aggregate exercise price of approximately $50 million are exercisable until 21 days following four quarters of commercial sales of Renazorb following receipt of TDAPA approval.
CY2023Q1	us-gaap	Preferred Stock Per Share Amounts Of Preferred Dividends In Arrears PreferredStockPerShareAmountsOfPreferredDividendsInArrears	1000
CY2023Q1	us-gaap	Stock And Warrants Issued During Period Value Preferred Stock And Warrants StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants	2800000	usd
CY2023Q1	us-gaap	Other Cash Equivalents At Carrying Value OtherCashEquivalentsAtCarryingValue	25400000	usd
CY2023Q1	us-gaap	Preferred Stock Dividend Rate Percentage PreferredStockDividendRatePercentage	0.14	pure
CY2023Q1	us-gaap	Payments Of Dividends PaymentsOfDividends	200000	usd
CY2023Q1	us-gaap	Dividends Payable Amount Per Share DividendsPayableAmountPerShare	6.36
CY2023Q1	us-gaap	Employee Stock Ownership Plan Esop Plan Description EmployeeStockOwnershipPlanESOPPlanDescription	(A) the liquidation preference with respect to such share of Series A-1 Preferred Stock, divided by (B) the conversion price, provided that, to the extent the share conversion would cause such Holder’s beneficial ownership to exceed 9.99%, such holder shall receive shares of Series A-2 Preferred Stock in lieu of common stock, on a one-for-one basis, with respect to the number of shares of common stock that exceed 9.99% ownership, (2) a Tranche A Warrant, (3) a Tranche B Warrant, and (4) a Tranche C Warrant.
CY2023Q1	us-gaap	Preferred Stock Dividends Per Share Cash Paid PreferredStockDividendsPerShareCashPaid	1000
CY2023Q1	uncy	Annual Rate Percentage AnnualRatePercentage	0.08	pure
CY2023Q1	us-gaap	Common Stock Dividends Shares CommonStockDividendsShares	1	shares
CY2023Q1	uncy	Fair Value Adjustment Of Warrant FairValueAdjustmentOfWarrant	2800000	usd
CY2023Q1	uncy	Fair Value Adjustment Of Warrant FairValueAdjustmentOfWarrant	13200000	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	157000888	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.64
CY2023Q1	uncy	Weighted Average Remaining Contractual Term Warrants Contingently Issuable WeightedAverageRemainingContractualTermWarrantsContingentlyIssuable	P2Y1M6D
CY2023Q1	uncy	Aggregate Intrinsic Value Warrants Contingently Issuable AggregateIntrinsicValueWarrantsContingentlyIssuable	229069000	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	157000888	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	0.64
CY2023Q1	uncy	Weighted Average Remaining Contractual Term Outstanding Ending Balance1 WeightedAverageRemainingContractualTermOutstandingEndingBalance1	P2Y1M6D
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	229069000	usd
CY2021Q3	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	1302326	shares
CY2022Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	352938	shares
CY2023Q1	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	352938	shares
CY2022Q1	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims		usd
CY2022Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2023Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1342670	shares
CY2022Q4	uncy	Weighted Average Exercise Price Options Outstanding Beginning WeightedAverageExercisePriceOptionsOutstandingBeginning	2.75
CY2023Q1	uncy	Weighted Average Remaining Contractual Term Outstanding WeightedAverageRemainingContractualTermOutstanding	P8Y5M19D
CY2022Q4	uncy	Aggregate Intrinsic Value Outstanding Beginningin Dollars AggregateIntrinsicValueOutstandingBeginninginDollars	52000	usd
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares	4000	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	1.66
CY2023Q1	uncy	Number Of Shares Underlying Outstanding Options Options Exercised NumberOfSharesUnderlyingOutstandingOptionsOptionsExercised	2181	shares
CY2023Q1	uncy	Weighted Average Exercise Price Options Exercised WeightedAverageExercisePriceOptionsExercised	3.27
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1336489	shares
CY2023Q1	uncy	Weighted Average Exercises Price Outstanding Ending WeightedAverageExercisesPriceOutstandingEnding	2.76
CY2023Q1	uncy	Sharebased Compensation Arrangement By Sharebased Payments Award Options Exercisable Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentsAwardOptionsExercisableWeightedAverageRemainingContractualTerm2	P8Y2M23D
CY2023Q1	uncy	Aggregate Intrinsic Value Outstanding Ending AggregateIntrinsicValueOutstandingEnding	643000	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	709899	shares
CY2023Q1	uncy	Weighted Exercise Price Option Vested And Exercisable WeightedExercisePriceOptionVestedAndExercisable	3.16
CY2023Q1	uncy	Share Based Weighted Average Remaining Contractual Term Shares Vested And Exercisable Share-basedWeightedAverageRemainingContractualTermSharesVestedAndExercisable	P7Y7M13D
CY2023Q1	uncy	Aggregate Intrinsic Value Options Vested And Exercisable AggregateIntrinsicValueOptionsVestedAndExercisable	208000	usd
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Number Of Shares Period Increase Decrease SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease	900000	shares
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P2Y1M6D
CY2021	uncy	Exercised Stock Option ExercisedStockOption	383721	shares
CY2021	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	119000	usd
CY2023Q1	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions	7365	shares
CY2023Q1	uncy	Unvested Options Amount UnvestedOptionsAmount	24000	usd
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	7000	usd
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	376349	shares
CY2022Q2	us-gaap	Weighted Average Number Of Shares Restricted Stock WeightedAverageNumberOfSharesRestrictedStock	10000	shares
CY2022Q2	us-gaap	Restricted Stock Expense RestrictedStockExpense	7200	usd
CY2022Q2	us-gaap	Option Contract Indexed To Equity Settlement Share Fair Value Per Share OptionContractIndexedToEquitySettlementShareFairValuePerShare	0.72
CY2023Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	4000	usd
CY2021Q3	us-gaap	Weighted Average Number Of Shares Restricted Stock WeightedAverageNumberOfSharesRestrictedStock	26738	shares
CY2021Q3	us-gaap	Restricted Stock Expense RestrictedStockExpense	100000	usd
CY2021Q3	us-gaap	Option Contract Indexed To Equity Settlement Share Fair Value Per Share OptionContractIndexedToEquitySettlementShareFairValuePerShare	3.74
CY2022Q1	uncy	Research And Development ResearchAndDevelopment	99000	usd
CY2023Q1	uncy	Research And Development ResearchAndDevelopment	82000	usd
CY2022Q1	us-gaap	Net Income Loss Allocated To Limited Partners NetIncomeLossAllocatedToLimitedPartners	-3537000	usd
CY2023Q1	us-gaap	Net Income Loss Allocated To Limited Partners NetIncomeLossAllocatedToLimitedPartners	-14575000	usd
CY2023Q1	us-gaap	Dividends Payable Current And Noncurrent DividendsPayableCurrentAndNoncurrent	192000	usd
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3537000	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-14767000	usd
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	15004617	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	15232406	shares
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.24
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.97
CY2022Q1	uncy	Options To Purchase Common Stock OptionsToPurchaseCommonStock	1187085	shares
CY2023Q1	uncy	Options To Purchase Common Stock OptionsToPurchaseCommonStock	1336489	shares
CY2022Q1	uncy	Warrants To Purchase Common Stock WarrantsToPurchaseCommonStock	4784193	shares
CY2023Q1	uncy	Warrants To Purchase Common Stock WarrantsToPurchaseCommonStock	4784193	shares
CY2023Q1	uncy	Contingently Issuable Warrants To Purchase Preferred Stock ContingentlyIssuableWarrantsToPurchasePreferredStock	157000888	shares
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5971278	shares
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	163121570	shares
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	Unicycive Therapeutics, Inc.
CY2022Q4	us-gaap	Derivative Liabilities DerivativeLiabilities		usd
CY2022Q4	us-gaap	Temporary Equity Value Excluding Additional Paid In Capital TemporaryEquityValueExcludingAdditionalPaidInCapital		usd
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Liquidation Preference Value PreferredStockLiquidationPreferenceValue	0	usd
CY2023Q1	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022Q1	us-gaap	Interest Income Other InterestIncomeOther		usd
CY2022Q1	us-gaap	Interest Expense InterestExpense		usd
CY2022Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense		usd
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	15232406	shares
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues		usd
CY2022Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants		usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue		usd
CY2023Q1	uncy	Weighted Average Exercise Price Warrants Exercised WeightedAverageExercisePriceWarrantsExercised
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue		usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue		usd
CY2022Q4	us-gaap	Excess Stock Shares Issued ExcessStockSharesIssued		shares
CY2022Q4	us-gaap	Excess Stock Shares Outstanding ExcessStockSharesOutstanding		shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber		shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised		shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
CY2023Q1	uncy	Aggregate Intrinsic Value Warrants Exercised AggregateIntrinsicValueWarrantsExercised		usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
CY2023Q1	uncy	Weighted Average Remaining Contractual Termin Years Options Forfeited WeightedAverageRemainingContractualTerminYearsOptionsForfeited
CY2023Q1	us-gaap	Stock Granted During Period Value Sharebased Compensation Forfeited StockGrantedDuringPeriodValueSharebasedCompensationForfeited		usd
CY2023Q1	uncy	Weighted Average Remaining Contractual Term Options Exercised WeightedAverageRemainingContractualTermOptionsExercised
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue		usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-14540000	usd
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-3537000	usd
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	15004617	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	15232406	shares
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.24
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.97
CY2022Q1	uncy	Contingently Issuable Warrants To Purchase Preferred Stock ContingentlyIssuableWarrantsToPurchasePreferredStock		shares
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001766140

Files In Submission

Name	View Source	Status
0001213900-23-040161-index-headers.html	Edgar Link	pending
0001213900-23-040161-index.html	Edgar Link	pending
0001213900-23-040161.txt	Edgar Link	pending
0001213900-23-040161-xbrl.zip	Edgar Link	pending
f10q0323ex31-1_unicycive.htm	Edgar Link	pending
f10q0323ex31-2_unicycive.htm	Edgar Link	pending
f10q0323ex32-1_unicycive.htm	Edgar Link	pending
f10q0323ex32-2_unicycive.htm	Edgar Link	pending
f10q0323_unicycivethera.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
f10q0323_unicycivethera_htm.xml	Edgar Link	completed
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
uncy-20230331.xsd	Edgar Link	pending
uncy-20230331_lab.xml	Edgar Link	unprocessable
uncy-20230331_cal.xml	Edgar Link	unprocessable
uncy-20230331_def.xml	Edgar Link	unprocessable
uncy-20230331_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$UNCY
Unicycive Therapeutics, Inc. Stock $uncy

2023 Q2 Form 10-Q Financial Statement

#000121390023040161 Filed on May 16, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$UNCY Unicycive Therapeutics, Inc. Stock $uncy

2023 Q2 Form 10-Q Financial Statement

#000121390023040161 Filed on May 16, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$UNCY
Unicycive Therapeutics, Inc. Stock $uncy